Skip to main content
Medistim logo

Medistim — Investor Relations & Filings

Ticker · MEDI ISIN · NO0010159684 LEI · 5967007LIEEXZXJOX483 OL Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2025-03-21 Transaction in Own Shar…
Country NO Norway
Listing OL MEDI

About Medistim

https://medistim.com/

Medistim is a medical technology company specializing in intraoperative quality assessment solutions. A pioneer and market leader in Transit Time Flow Measurement (TTFM), the company develops and manufactures advanced medical devices for use during surgical procedures. Its flagship MiraQ™ system uniquely combines TTFM with high-frequency ultrasound imaging, providing surgeons with real-time data to verify graft function and blood flow. This technology is applied in cardiac, vascular, and transplant surgery to enhance procedural quality control and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Medistim ASA – Status on share buyback
Transaction in Own Shares Classification · 100% confidence The document is titled 'Medistim ASA – Status on share buyback' and details the number of shares purchased by the company during a specific period (March 11 to March 21, 2025) as part of a previously announced repurchase program. This directly relates to the company acquiring its own shares. According to the definitions, 'Transaction in Own Shares (Code: POS)' covers 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. The document provides the status update and transaction details, making POS the most appropriate classification.
2025-03-21 English
Medistim ASA – Status on share buyback
Transaction in Own Shares Classification · 100% confidence The document is titled 'Medistim ASA – Status on share buyback' and explicitly details the number of shares purchased by the company during a specific period (March 11 to March 14, 2025) as part of a previously announced repurchase program. It provides transaction details (date, number of shares, average price) and updates the total holding of own shares. This directly corresponds to the definition of 'Transaction in Own Shares' (POS). The document length is short (2264 chars), but it is a status update/report of transactions, not merely an announcement that a report is attached, making POS a more specific fit than RPA or RNS.
2025-03-17 English
Medistim ASA – Initiation of share buy-back programme
Transaction in Own Shares Classification · 100% confidence The document explicitly announces the 'Initiation of share buy-back programme' by Medistim ASA. It details the commencement date, end date, maximum number of shares, maximum consideration (NOK 35,000,000), and the purpose (share-based incentive plan). This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase programs.
2025-03-11 English
Medistim ASA – Initiation of share buy-back programme
Transaction in Own Shares Classification · 100% confidence The document explicitly announces the 'Initiation of share buy-back programme' by Medistim ASA. It details the commencement date, end date, maximum number of shares, maximum consideration (NOK 35,000,000), and the purpose (share-based incentive plan). This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase programs.
2025-03-11 English
NOTIFICATION OF TRADE IN MEDISTIM ASA
Major Shareholding Notification Classification · 99% confidence The document explicitly states it is a 'NOTIFICATION OF TRADE' involving the purchase of shares by an entity controlled by the Chairman of the Board of Directors of Medistim ASA. This directly relates to personal share transactions by company directors and executives (insider trades). This aligns perfectly with the definition of Director's Dealing (DIRS). The document is short and contains specific transaction details, confirming it is the primary notification, not an announcement of a report.
2025-03-04 English
Results for the fourth quarter and preliminary financial results for Medistim for 2024
Investor Presentation Classification · 95% confidence The document text explicitly covers 'Fourth Quarter and Full Year 2024 Preliminary Financial Results', includes detailed financial statements (Profit & Loss, Balance Sheet, Cash Flow) for Q4 2024 and FY 2024, key performance indicators (KPIs), and management commentary on business segments and strategy. This structure is characteristic of a comprehensive financial report covering a full fiscal year and a recent quarter. Since it contains full financial statements and detailed analysis, it is more comprehensive than a simple Earnings Release (ER). It is not a proxy statement (DEF 14A) or an announcement of a report (RPA). Given the comprehensive nature covering the full year and detailed financials, it aligns best with an Interim/Quarterly Report (IR) if it were only quarterly, but since it covers the full year results, it strongly suggests the content of an Annual Report (10-K) or a very detailed Interim Report. However, the document is titled 'Preliminary Financial Results' and focuses heavily on Q4 and FY 2024 performance review, which often precedes the final audited 10-K filing. In many contexts, a detailed presentation summarizing full-year results, especially one that references the Annual Report for 2023 risks, functions as the core content of an Investor Presentation (IP) or a detailed Earnings Release package. Given the presentation format (slides, CEO/CFO commentary, detailed segment breakdowns, and strategy review), 'Investor Presentation' (IP) is the most accurate classification for this specific document type, which is a detailed review package for investors covering the full year's performance.
2025-02-28 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.